UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

Investigating the Impact of COVID-19 on Mobility Condition

Acharya, Sandip

2023

Volltextzugriff (PDF)

Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)

Journal of allergy and clinical immunology, 2022-05, Vol.149 (5), p.1675-1682.e3

2022

Volltextzugriff (PDF)

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study

Annals of internal medicine, 2018-04, Vol.168 (7), p.461

2018

Volltextzugriff (PDF)

1055-P: The Machine Learning Prediction Model NASHmap Identifies Higher Insulin Resistance in Type 2 Diabetes Mellitus (T2DM) Patients at Risk for Nonalcoholic Steatohepatitis (NASH)

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd

British journal of haematology, 2017-10, Vol.179 (2), p.219-228

2017

Volltextzugriff (PDF)

ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7005-7005

2019

Volltextzugriff (PDF)

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Blood, 2017-12, Vol.130, p.1598-1598

2017

Volltextzugriff (PDF)

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Blood, 2017-12, Vol.130, p.2878-2878

2017

Volltextzugriff (PDF)

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENEST xtnd

British journal of haematology, 2017-10, Vol.179 (2), p.219-228

2017

Volltextzugriff (PDF)

Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7003-7003

2018

Volltextzugriff (PDF)

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

Blood, 2015-12, Vol.126 (23), p.4029-4029

2015

Volltextzugriff (PDF)

ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Clinical lymphoma, myeloma and leukemia, 2017-09, Vol.17, p.S314-S315

2017

Volltextzugriff (PDF)

Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7054-7054

2016

Volltextzugriff (PDF)

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Blood, 2013-11, Vol.122 (21), p.4009-4009

2013

Volltextzugriff (PDF)

Prospective, observational registry of branded imatinib (IM) and nilotinib (NIL) exposure in pregnant women: Voluntary post-authorization safety study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS6638-TPS6638

2012

Volltextzugriff (PDF)

Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7025-7025

2014

Volltextzugriff (PDF)

ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib

Clinical lymphoma, myeloma and leukemia, 2018-09, Vol.18, p.S222-S222

2018

Volltextzugriff (PDF)

Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up

Blood, 2013-11, Vol.122 (21), p.94-95

2013

Volltextzugriff (PDF)

Electronic materials for solution-processed TFTs

Materials research express, 2023-08, Vol.10 (8), p.82002

2023

Volltextzugriff (PDF)

Diurnal carbon dynamics in a mangrove-dominated tropical estuary (Sundarbans, India)

Estuarine, coastal and shelf science, 2019-11, Vol.229, p.106426, Article 106426

2019

Volltextzugriff (PDF)

Prevalence of abuse among the elderly population of Syangja, Nepal

BMC public health, 2021-07, Vol.21 (1), p.1-1348, Article 1348

2021

Volltextzugriff (PDF)

Polysaccharide-rich fraction of Termitomyces eurhizus accelerate healing of indomethacin induced gastric ulcer in mice

Glycoconjugate journal, 2013-11, Vol.30 (8), p.759-768

2013

Volltextzugriff (PDF)

Perspectives on chick embryo models in developmental and reproductive toxicity screening

Reproductive toxicology (Elmsford, N.Y.), 2024-06, Vol.126, p.108583, Article 108583

2024

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Englisch
(91)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(30)
Physical Sciences
(14)
Case Report
(8)
Humans
(8)
Technology
(8)
Materials Science
(7)
General & Internal Medicine
(6)
Materials Science, Multidisciplinary
(6)
Chemistry
(5)
Animals
(4)
Chemistry, Physical
(4)
Environmental Sciences & Ecology
(4)
Medicine, General & Internal
(4)
Oceanography
(4)
Patients
(4)
Adult
(3)
Aged
(3)
Aggregation-Induced Emission
(3)
Biomedical And Life Sciences
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Investigating the Impact of COVID-19 on Mobility Condition

Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study

1055-P: The Machine Learning Prediction Model NASHmap Identifies Higher Insulin Resistance in Type 2 Diabetes Mellitus (T2DM) Patients at Risk for Nonalcoholic Steatohepatitis (NASH)

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd

ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL)

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENEST xtnd

Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Prospective, observational registry of branded imatinib (IM) and nilotinib (NIL) exposure in pregnant women: Voluntary post-authorization safety study

Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr

ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib

Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up

Electronic materials for solution-processed TFTs

Diurnal carbon dynamics in a mangrove-dominated tropical estuary (Sundarbans, India)

Prevalence of abuse among the elderly population of Syangja, Nepal

Polysaccharide-rich fraction of Termitomyces eurhizus accelerate healing of indomethacin induced gastric ulcer in mice

Perspectives on chick embryo models in developmental and reproductive toxicity screening

Suchergebnisse filtern